Another study showed that miR-19a/b inhibition in vitro and in vivo GBM models resulted in repression of glioma cell proliferation partially by upregulating RUNX3, followed by blocking of the Wnt/β-catenin pathway. The gene discussed is RUNX3; the disease is central nervous system cancer.